National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Naloxone (Nyxoid®) intranasal spray. HTA ID: 20019

Naloxone (Nyxoid®) intranasal spray is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings. Nyxoid® is indicated in adults and adolescents aged 14 years and over. Nyxoid® is not a substitute for emergency medical care.


NCPE Assessment Process Complete
Rapid review commissioned 14/04/2020
Rapid review completed 12/05/2020
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that naloxone (Nyxoid®) intranasal spray be considered for reimbursement*.


*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.